Curanex Pharmaceuticals (CURX) Non Operating Interest Expenses (2025)
Curanex Pharmaceuticals' (CURX) quarterly Non Operating Interest Expenses came in at $4090.0 in Q3 2025, up 32.32% quarter-over-quarter from $3091.0 in Q2 2025.
Powered by 
Analysis
Curanex Pharmaceuticals (CURX) Non Operating Interest Expenses (2025) Analysis & Trends
Curanex Pharmaceuticals (CURX) has reported Non Operating Interest Expenses for 1 consecutive years, with $4090.0 the latest figure, recorded in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 281.00 Mn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | - |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | -462.00 Mn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | - |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | -333.60 Mn |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | 23.78 Mn |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 582,000.00 |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 2.90 Mn |
| 10 | Curanex Pharmaceuticals | 5.97 Mn | 3.03 Mn | - | - |